Latest Breaking News On - Clinj am soc - Page 2 : comparemela.com

Novartis Pharma AG: Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company s IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs.

United statesSloan simpsonNicole zinsli sommLambers heerspinkJonathan grahamSatoshi sugimotoParag mahantiMarlena abdinoorImke kappesIsabella zinckNovartis fabhaltaMichael meoLoreto mdaBartonm endothelinExchange commissionEuropean renal association

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35 1% proteinuria reduction vs placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2

United statesCzech republicImke kappesMarlena abdinoorDavid soergelMichael meoSloan simpsonJonathan grahamParag mahantiIsabella zinckMarianne silkjDavid kavanaghNicole zinsli sommSatoshi sugimotoFaculty of medical sciences at newcastle universityGlomerular diseases work group

Risk Factors for IgA Nephropathy Recurrence After Kidney Transplant

Younger age at the time of kidney transplantation, faster progression to end-stage renal disease, a history of kidney transplantation, and no induction therapy were associated with IgAN recurrence, which was linked to poorer graft survival.

Sichuan universityCochrane libraryTurun songIga nephropathyBerger diseaseKidney transplantationClinj am socImmunoglobulina nephropathyKidney transplantEnd stage renal disease

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)

Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1;.

Czech republicUnited statesSloan simpsonSatoshi sugimotoParag mahantiIsabella zinckJonathan grahamJulie masowSamir shahRichard jarvisShreeram aradhyeZain iqbalNicole zinsli sommImke kappesMarlena abdinoorMichael meo

Novartis Pharma AG: Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)

Novartis Pharma AG: Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Czech republicUnited statesSamir shahJonathan grahamIsabella zinckSatoshi sugimotoRichard jarvisShreeram aradhyeStefan klotterZain iqbalSloan simpsonImke kappesNicole zinsli sommMichael meoJulie masowParag mahanti